<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Screening for associated conditions and comorbidities in children with sickle cell disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Screening for associated conditions and comorbidities in children with sickle cell disease</h1>
<div class="graphic"><div class="figure"><div class="ttl">Screening for associated conditions and comorbidities in children with sickle cell disease</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1">Condition/comorbidity</td> <td class="subtitle1">Screening test(s) used</td> <td class="subtitle1">Age at which screening is started</td> <td class="subtitle1">Action(s) to take if screening is abnormal</td> </tr> <tr> <td class="subtitle2_left" colspan="4">General pediatric issues that may require special attention in patients with SCD (assess at all routine visits)</td> </tr> <tr> <td class="indent1">Asthma</td> <td> <ul> <li>Symptom screening by ROS</li> <li>History of recurrent wheezing and/or recurrent ACS</li> </ul> </td> <td>Infancy</td> <td> <ul> <li>Referral to an asthma specialist for spirometry and to optimize asthma management</li> </ul> </td> </tr> <tr> <td class="indent1">Depression and other mental health issues</td> <td> <ul> <li>Screening questions or questionnaires</li> </ul> </td> <td>Once old enough to answer screening questions, typically by school age</td> <td> <ul> <li>Referral to mental health provider</li> </ul> </td> </tr> <tr> <td class="indent1">Growth failure and delayed puberty</td> <td> <ul> <li>Measurement of height, weight, and assessment of pubertal stage</li> </ul> </td> <td>Infancy</td> <td> <ul> <li>Referral to endocrinologist</li> </ul> </td> </tr> <tr> <td class="indent1">Hypertension</td> <td> <ul> <li>Manual or automated blood pressure measurement</li> </ul> </td> <td>Infancy</td> <td> <ul> <li>Referral to nephrologist</li> </ul> </td> </tr> <tr> <td class="indent1">OSA</td> <td> <ul> <li>Screening questions regarding frequency of OSA symptoms</li> </ul> </td> <td>Age 2 years</td> <td> <ul> <li>Refer to pulmonary/sleep medicine specialist for PSG</li> <li>If PSG confirms OSA, refer to otolaryngologist for possible adenotonsillectomy</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">SCD-specific issues (assess at least annually)</td> </tr> <tr> <td class="indent1">Nephropathy</td> <td> <ul> <li>Measurement of urinary protein (eg, urinalysis or urine protein-to-creatinine ratio)</li> <li>Serum creatinine</li> </ul> </td> <td>By age 10 years*</td> <td> <ul> <li>Referral to nephrology</li> </ul> </td> </tr> <tr> <td class="indent1">Pulmonary hypertension</td> <td> <ul> <li>Echocardiogram</li> </ul> </td> <td>Once between age 8 to 18 years<sup>¶</sup></td> <td> <ul> <li>Referral to cardiology</li> </ul> </td> </tr> <tr> <td class="indent1">Retinopathy</td> <td> <ul> <li>Dilated eye examination</li> </ul> </td> <td>10 years</td> <td> <ul> <li>Referral to ophthalmology</li> </ul> </td> </tr> <tr> <td class="indent1">Stroke</td> <td> <ul> <li>TCD (patients with Hb SS or Hb S-beta<sup>0</sup> thalassemia only)</li> <li>Assess for neurocognitive or other neurologic deficits (eg, developmental delay, marked decline in school performance, frequent headaches)</li> </ul> </td> <td>2 years<sup>Δ</sup></td> <td> <ul> <li>Obtain MRI/MRA if TCD is abnormal or if there are clinical concerns</li> <li>Referral to neurology for patients with confirmed stroke</li> <li>Follow-up abnormal TCD results with repeat testing<sup>Δ</sup></li> <li>For persistently abnormal flow velocity on TCD, primary prophylaxis with chronic transfusion is generally indicated<sup>Δ</sup></li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes">SCD: sickle cell disease;
ROS: review of symptoms;
ACS: acute chest syndrome;
OSA: obstructive sleep apnea;
PSG: polysomnography;
TCD: transcranial Doppler;
Hb: hemoglobin;
MRI: magnetic resonance imaging,
MRA: magnetic resonance angiography.<br/>
* The optimal screening test and intervals for testing for sickle cell nephropathy are uncertain. We typically begin annual screening at age 10 years with a spot urine protein-to-creatinine ratio and serum creatinine level. Other experts start screening as early as age 3 years.<br/>
¶ There is disagreement among experts, including UpToDate authors, about the benefit and timing of the screening echocardiogram in asymptomatic adolescents with SCD. An echocardiogram should be performed in patients who develop symptoms suggestive of pulmonary hypertension (eg, exercise intolerance, chest pain, or otherwise unexplained respiratory symptoms). In the absence of concerning symptoms, it is reasonable to obtain a screening echocardiogram once during adolescence. Refer to UpToDate topic on pulmonary hypertension in SCD for additional details.<br/>
Δ For children with Hb SS or Hb S-beta<sup>0</sup> thalassemia, TCD screening begins at age 2 years and continues through age 16 years (if feasible). Screening is not required for individuals with other forms of SCD (eg, Hb SC, Hb S-beta<sup>+</sup> thalassemia), although it may be appropriate in those with evidence of severe disease such as frequent episodes of acute chest syndrome or vaso-occlusive pain episodes. If performed, it should be noted that the risk stratification parameters established for patients with Hb SS may not apply to those with other genotypes. Refer to UpToDate topic on prevention of stroke in SCD for additional details of the interval of follow-up for abnormal TCD results and indications for chronic transfusion therapy.</div><div id="graphicVersion">Graphic 134370 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
